RxDoctor Payments DataLook up a doctor →

David Wilkett, DO

Cardiovascular Disease · Tulsa, OKNPI 1922080860

Payments from drug & device makers

$104,155in general payments, 2019–2025

Across 680 payments — averaging $153.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$42K
  • Novartis$26K
  • Elutia, Inc.$16K
  • Abbott$6K
  • Boston Scientific$4K
  • GE HealthCare$2K
  • plus $9K from 38 others

What the payments were for

  • Travel & lodging$2,41010%
  • Food & beverage$21,88589%
  • Education$2191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$104,155 in reported general payments places this provider in the 95th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$105,001
Medicare patients
518
Services billed
2,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan312$238,453
EliquisApixaban232$165,364
JardianceEmpagliflozin230$148,401
XareltoRivaroxaban126$94,126
Repatha SureclickEvolocumab92$61,330
Praluent PenAlirocumab30$18,510
BrilintaTicagrelor27$12,586
MultaqDronedarone Hcl15$11,571
Ranolazine ErRanolazine83$5,511
Atorvastatin Calcium403$4,590
Metoprolol Succinate340$3,289
Rosuvastatin Calcium219$1,513
Losartan Potassium192$1,496
Nitroglycerin112$1,207
SynthroidLevothyroxine Sodium25$1,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$26,292$238,453312 claims
PfizerEliquis$350$165,364232 claims
Boehringer IngelheimJardiance$206$148,401230 claims
Johnson & JohnsonXarelto$781$94,126126 claims
AstraZenecaBrilinta$315$12,58627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 164 cardiovascular disease providers in Oklahoma.

Other cardiovascular disease in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →